Corton Capital’s Immuneering IMRX Stock Holding History

Corton Capital’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,536	Closed	-$76.7K	–	617
2024 Q1	$76.7K	Sell	26,536 -419	-2%	-$2.35K	0.03%	486
2023 Q4	$198K	Buy	26,955 +8,108	+43%	+$54K	0.06%	484
2023 Q3	$145K	Buy	+18,847	New	+$173K	0.07%	357

Other funds holding IMRX

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Corton Capital's IMRX Position: Q2 2024 in Review

Corton Capital sold out of Immuneering (IMRX) in Q2 2024, closing a stake of 26,536 shares — an estimated $76.7K sold.

Corton Capital first reported a position in IMRX in Q3 2023 and held it in 3 quarters. The position peaked at $198K in Q4 2023. 59 funds tracked by Wall St. Rank hold IMRX as of Q2 2024.

Corton Capital reported no remaining Immuneering position as of Q2 2024 after selling out during the quarter.
Corton Capital sold 26,536 Immuneering shares in Q2 2024, an estimated $76.7K.
Corton Capital first reported a position in Immuneering in Q3 2023 and held it in 3 quarters.
Corton Capital's Immuneering position peaked at $198K in Q4 2023.
59 funds tracked by Wall St. Rank held Immuneering as of Q2 2024.

Based on Corton Capital's 13F filing for Q2 2024, filed 14 Aug 2024.